Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Orion Corporation
New company licenses obicetrapib from Amgen after previous companies’ setbacks in CETP class and works with FDA on a Phase III protocol. BMS buys protein-engineering specialist Forbius.
While Xtandi has positive new survival data in prostate cancer, other rivals in the competitive market are reporting the same at ASCO.
The Bayh-Dole act of 1980 facilitated deal-making between private-sector firms and research institutions, largely seeding the US biotech industry. Plus, an overview of the latest tech transfer deals.
The number of new active substances launched in their first market in 2019 dropped as 2018’s superlative performance gave way to something more usual.
- Medical Devices
- Generic Drugs
- Other Names / Subsidiaries
- Orion Corporation
- Orion Diagnostica Oy
- Orion Pharma
- Orion Oyj